NASDAQ · TNYA
Healthcare · Biotechnology
$0.36
Up+$0.01 (+2.66%)
Updated Nov 4, 2026, 10:32 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TNYA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TNYA closed at $0.36 after 21 trading sessions, down 34.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.3578 | $0.3778 | $0.351 | $0.3603 | 1.66M |
| Nov 2, 2026 | $0.3716 | $0.3811 | $0.361 | $0.361 | 2.29M |
| Oct 30, 2026 | $0.3936 | $0.40 | $0.3656 | $0.3674 | 2.66M |
| Oct 29, 2026 | $0.40 | $0.4179 | $0.3971 | $0.3984 | 1.78M |
| Oct 28, 2026 | $0.41 | $0.4146 | $0.4001 | $0.4038 | 1.21M |
| Oct 27, 2026 | $0.42 | $0.429 | $0.3925 | $0.4014 | 2.14M |
| Oct 26, 2026 | $0.3919 | $0.4188 | $0.385 | $0.4086 | 3.44M |
| Oct 23, 2026 | $0.3945 | $0.397 | $0.3813 | $0.389 | 1.7M |
| Oct 22, 2026 | $0.395 | $0.4081 | $0.386 | $0.388 | 1.72M |
| Oct 21, 2026 | $0.41 | $0.4184 | $0.39 | $0.3902 | 2.19M |
| Oct 20, 2026 | $0.3807 | $0.419 | $0.38 | $0.41 | 3.26M |
| Oct 19, 2026 | $0.38 | $0.3886 | $0.362 | $0.3776 | 3.01M |
| Oct 16, 2026 | $0.41 | $0.417 | $0.3703 | $0.3807 | 6.84M |
| Oct 15, 2026 | $0.39 | $0.43 | $0.39 | $0.4084 | 5.01M |
| Oct 14, 2026 | $0.50 | $0.51 | $0.3601 | $0.3905 | 18.15M |
| Oct 13, 2026 | $0.569 | $0.57 | $0.5172 | $0.521 | 2.56M |
| Oct 12, 2026 | $0.562 | $0.5774 | $0.545 | $0.5655 | 2.51M |
| Oct 9, 2026 | $0.539 | $0.59 | $0.538 | $0.5803 | 4.3M |
| Oct 8, 2026 | $0.53 | $0.5471 | $0.5211 | $0.5442 | 3.64M |
| Oct 7, 2026 | $0.53 | $0.5548 | $0.53 | $0.5334 | 3.73M |
| Oct 6, 2026 | $0.57 | $0.577 | $0.5421 | $0.5465 | 2.7M |
The latest Smart Investors Daily articles mentioning TNYA.
Company
Market Activity
Research & News
TNYA research
Company profile and research snapshot.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | Buy | — |
| Dec 18, 2025 | Canaccord Genuity | Buy | — |
| Dec 12, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 12, 2025 | Chardan Capital | Buy | — |
| Nov 10, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 9, 2026
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
Benzinga · Mar 5, 2026
Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.
Benzinga · Mar 5, 2026
Benzinga · Mar 5, 2026
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TNYA.
